Study links GLP-1 drugs to modest hair loss risk

Suomi

A new analysis of patient records shows that adults with type 2 diabetes who take GLP-1 receptor agonists face a higher rate of alopecia than those on other common diabetes medications.

The study, published July 22, 2026, in The BMJ, examined electronic health records from Penn Medicine covering patients treated from January 2019 to September 2024.

After adjustments for age, sex, body mass index and other factors, GLP-1 users showed a 37 percent higher risk of alopecia compared with SGLT-2 inhibitor users and a 68 percent higher risk compared with DPP-4 inhibitor users.

The increased risk was confined to non-scarring alopecia, a form that may allow hair to regrow. Absolute rates remained low at roughly 6 to 7 cases per 1,000 person-years.

Researchers noted that rapid weight loss associated with the drugs could contribute to the effect through nutrient deficiencies or hormonal shifts, though the study could not confirm causation.

Liittyvät artikkelit

Illustration of high-risk patients benefiting from GLP-1 drugs like Ozempic with reduced heart risks
AI:n luoma kuva

Review finds GLP-1 drugs linked to lower risk of heart attack, stroke and death in high-risk patients

Raportoinut AI AI:n luoma kuva Faktatarkistettu

A large review of cardiovascular outcome trials found that people taking GLP-1 receptor agonists—drugs that include semaglutide (sold as Ozempic)—had a lower risk of major heart-related events than those given placebo. The analysis pooled results from 11 trials involving more than 90,000 participants, with an average follow-up of nearly three years, and reported benefits across patient subgroups including those with and without diabetes.

Oral GLP-1 pill shows strong results in diabetes trial

A new experimental oral medication called elecoglipron improved blood sugar control and promoted weight loss in adults with type 2 diabetes during a phase 2b trial. Results from the SOLSTICE study were presented at the American Diabetes Association's Scientific Sessions and published in The Lancet.

Japanese study links GLP-1 response to ‘external eating’ habits in people with type 2 diabetes

Raportoinut AI Faktatarkistettu

A year-long observational study in Japan suggests that people with type 2 diabetes who tend to overeat in response to tempting food cues such as sight and smell may see greater weight loss—and possibly better blood-sugar improvement—after starting GLP-1 receptor agonists, while those with primarily emotional eating patterns show less consistent links to long-term outcomes.

Teknologia

AI analysis of Reddit posts highlights potential underrecognized side effects linked to GLP-1 drugs

Terveys

Trojan horse obesity drug boosts weight loss in mice

Terveys

Study links Ozempic to lower depression and anxiety risks

Study links PAM gene variants to weaker blood-sugar response to GLP-1 drugs such as Ozempic

Researchers say genetic variants in the PAM gene may help explain why some people with Type 2 diabetes get less blood-sugar benefit from GLP-1 receptor agonist drugs such as Ozempic, a phenomenon they describe as “GLP-1 resistance.”

Rutgers study finds GLP-1 drug use is tied to a weaker link between impulsivity and self-reported violence

Raportoinut AI Faktatarkistettu

A study from Rutgers University reports that adults currently using GLP-1 receptor agonist medications—including semaglutide brands Ozempic and Wegovy—showed a substantially weaker association between impulsivity and self-reported violent behavior than former users. The research, published June 17, 2026 in the journal Criminology, was based on a 2025 U.S. survey and does not establish cause and effect.

Stanford scientists report appetite-suppressing peptide that reduced weight in mice and pigs

Stanford Medicine researchers say they have identified a naturally occurring 12–amino-acid peptide, BRP, that suppressed appetite and reduced body weight in animal studies. The team used a computational tool dubbed “Peptide Predictor” to identify the molecule, and reported that BRP produced anti-obesity effects in mice and minipigs without signs of nausea- or aversion-like responses seen with some GLP-1–based drugs.

26. heinäkuuta 2026 00.20

Oral GLP-1 drugs reduce food reward signals in mice

24. heinäkuuta 2026 12.53

High costs limit access to GLP-1 weight loss drugs

9. heinäkuuta 2026 15.39

Semaglutide dosing mistakes fuel rise in poison control calls

20. kesäkuuta 2026 04.21

Updated POWER framework urges multidisciplinary obesity care beyond GLP-1 drugs

16. kesäkuuta 2026 12.55

Study presented at ENDO 2026 links semaglutide to fewer fractures in people with type 2 diabetes

16. kesäkuuta 2026 07.37

Claims-data study finds many people with type 2 diabetes restart GLP-1 drugs after stopping

14. kesäkuuta 2026 20.36

Study: Physical activity fell after some patients with obesity started GLP-1 drugs

6. kesäkuuta 2026 09.59

Study links GLP-1 drugs to lower breast cancer risk

22. toukokuuta 2026 11.06

Study finds GLP-1 hormone at very low levels in arthritic joint fluid

5. toukokuuta 2026 14.05

Study finds people who use Ozempic-like drugs for weight loss face added stigma

Tämä verkkosivusto käyttää evästeitä

Käytämme evästeitä analyysiä varten parantaaksemme sivustoamme. Lue tietosuojakäytäntömme tietosuojakäytäntö lisätietoja varten.
Hylkää